Document Detail


Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
MedLine Citation:
PMID:  23286859     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Products that are currently used in the treatment of chronic hepatitis B include interferon-alpha (IFNa: standard or pegylated) (PEG-IFNa) and nucleos(t)ide analogues (NAs). NAs are used in most HBeAg-negative chronic hepatitis B patients for several reasons. They can be prescribed to all chronic HBV patients, even those with contraindications to IFNa; and even IFNa candidates are usually treated with NAs because of their advantages. Administration of NAs is easier (one oral tablet per day compared with subcutaneous IFNa injections), tolerance is excellent and the safety profile is good, whereas IFNa may have adverse events and often worsens the patients' quality of life. The current first-line NA options, entecavir (ETV) and tenofovir (TDV), have minimal or no risk of long-term resistance and a virological response is achieved in almost 100% of adherent HBeAg-negative patients, thus modifying the long-term outcome. The need for long-term, perhaps indefinite, treatment is the main limitation of NAs and the finite duration (48 weeks), the main advantage of IFNa, especially in young patients of reproductive age. However, at most 25% of IFNa-treated HBeAg-negative patients achieve a sustained off-treatment response and therefore >75% of them will eventually receive NAs, even if they start with IFNa. As there will always be concerns about safety and family planning issues with long-term NA therapy, NAs should be used carefully, particularly in young chronic hepatitis B patients with mild liver disease. Novel therapeutic options are needed to increase the rates of HBsAg loss and sustained off-treatment responses.
Authors:
George V Papatheodoridis
Related Documents :
17894699 - Psychological distress and coping strategies in patients with psoriasis: the psychae st...
19844609 - Radiation therapy and psychological distress in gynecologic oncology patients: outcomes...
18946269 - The impact of event scale--revised: a quick measure of a patient's response to trauma.
22502959 - Performance of 2 commercial real-time polymerase chain reaction assays for the detectio...
2394979 - A description of patients diagnosed with dsm-iii-r generalized anxiety disorder.
9764139 - Emotional management therapy in early psychosis.
21740539 - Ten-year experiences with tetanus at a tertiary hospital in northwestern tanzania: a re...
21446079 - Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis.
19919189 - Patient satisfaction with physician-patient communication during telemedicine.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  151-6     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
2nd Department of Internal Medicine, Athens University Medical School Hippokration General Hospital of Athens, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
Next Document:  Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?